Fifteenth In Vivo Lentiviral Vector-Based Therapeutic Technology Added to VIVEbiotech’s CGT Platform

Growing interest in in vivo cell and gene therapies is driving significant investment, given their potential to address some of the manufacturing and commercialization challenges associated with current ex vivo approaches.

The post Fifteenth <i>In Vivo</i> Lentiviral Vector-Based Therapeutic Technology Added to VIVEbiotech’s CGT Platform appeared first on GEN - Genetic Engineering and Biotechnology News.